Medtronic (MDT) Stock Still Looks Like A Bargain After 23% Returns
Medtronic stock is coming off a three year gain of 22.6%. A fresh intrinsic value estimate based on a Discounted Cash Flow (DCF) approach still points to a meaningful discount to where the shares trade today. With the broader valuation checks also leaning cheap, investors are weighing whether the recent performance has fully reflected that potential value gap.
- Over the past three years Medtronic has returned 22.6%, which is enough to reward patient holders but not so strong that it clearly rules out further upside if the valuation case holds.
- Expectations that Medtronic can keep converting a large installed base of medical devices into steady cash flows may support the equity story. Any pressure on pricing or reimbursement for its therapies is a key risk that could limit how much of that cash flow reaches shareholders.
- The broader valuation checks suggest Medtronic screens as relatively cheap, with a high value score of 5 out of 6 and a DCF intrinsic value estimate sitting about 22.6% above the recent market price.
The issue now is whether that apparent discount in Medtronic’s valuation offers a reasonable entry point or simply reflects the risks the market already sees in the business.
Compare Medtronic's valuation gap with a curated list of other companies that also screen as potentially mispriced using the 45 high quality undervalued stocks.
Is Medtronic Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here uses Medtronic’s projected cash flows to estimate what the stock could be worth today. Medtronic generated about $5.43b in free cash flow over the latest twelve months in reporting currency terms, and the model assumes those cash flows keep growing rather than shrinking. Feeding those projections into a two stage free cash flow to equity framework produces an estimated intrinsic value of about $118 per share.
That DCF value sits above the current share price and implies Medtronic trades at roughly a 22.6% discount to this intrinsic estimate. For investors, the key question is whether the cash flow profile behind that figure looks durable, since the model leans on steady growth from an already large base of medical devices.
On this DCF view, Medtronic stock currently screens as undervalued relative to its projected cash generation.
Our Discounted Cash Flow (DCF) analysis suggests Medtronic is undervalued by 22.6%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.
Is Medtronic Still Cheap on Earnings?
For a mature medical devices group like Medtronic, the P/E ratio is a straightforward way to see what investors are paying for each dollar of current earnings.
Medtronic trades on a P/E of about 24.3x. That sits below the wider medical equipment industry average of roughly 26.9x and also below the peer group average near 32.6x. A fair P/E multiple that adjusts for Medtronic’s size, margins, sector and risk profile comes out at about 30.6x, which is higher than where the stock trades today.
The gap between the current P/E and this fair multiple suggests the market is applying a discount to Medtronic relative to what the model implies for a company with its characteristics. For investors, the key question is whether that discount reflects concerns that prove persistent or if it points to mispricing.
On the P/E multiple, Medtronic stock appears undervalued compared with both its tailored fair ratio and typical peers in the medical equipment industry.
See what the numbers say about this price — find out in our valuation breakdown.
The Medtronic Narrative: What Would Justify Today's Price?
Narratives for Medtronic pick up where this valuation puzzle leaves off and explain what mix of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than today's market price on Simply Wall St's Community page. Rather than relying on a single model output, each narrative sets out the assumptions behind its view of fair value so you can compare those against Medtronic's actual results over time.
The community is split on Medtronic, with one side focused on product and pipeline momentum and the other more wary about what the current profile already prices in.
Bull case: 7% undervalued
"Medtronic's investments and breakthroughs in digital health technologies, robotics (Hugo), next-generation sensors, and AI-enabled ecosystems (e.g., spine AiBLE, advanced neuromodulation) align with industry-wide digital transformation and minimally invasive trends..."
Read the full Bull Case to see why Medtronic could be undervalued
Bear case: roughly fairly valued
"Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable..."
Read the full Bear Case to see why Medtronic could be overvalued
Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!
The Bottom Line
For Medtronic, both the Discounted Cash Flow (DCF) intrinsic value estimate and the P/E based view point to the same conclusion. The stock screens as undervalued on cash generation and on earnings relative to peers and its tailored fair multiple. With broader checks also leaning supportive, the key question is whether Medtronic can keep turning its installed base into reliable cash flow without material pressure from pricing or reimbursement. That tension between apparent value and those business risks is central in determining whether the current discount represents an opportunity or a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com